Literature DB >> 7613161

Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic.

R Beasley1, N Pearce, J Crane, C Burgess.   

Abstract

In response to the evidence that fenoterol was a major cause for the second epidemic of asthma deaths in New Zealand, the Department of Health severely restricted its availability, thereby allowing an 'experiment in prevention' to be undertaken. These regulatory actions, which effectively removed fenoterol from the market in New Zealand, were associated with a sudden and marked reduction in asthma mortality, providing further evidence for a causative role of fenoterol in the epidemic of asthma deaths in New Zealand.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7613161     DOI: 10.1159/000237016

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  5 in total

1.  Asthma mortality in Australia 1920-94: age, period, and cohort effects.

Authors:  R Taylor; E Comino; A Bauman
Journal:  J Epidemiol Community Health       Date:  1997-08       Impact factor: 3.710

Review 2.  Serious adverse events and death associated with treatment using long-acting beta-agonists.

Authors:  Fernando D Martinez
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

3.  Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  BMC Med       Date:  2015-02-05       Impact factor: 8.775

4.  Evaluation of pharmacotherapy of obstructive airway diseases in the Montenegrin outpatient care: comparison with two Scandinavian countries.

Authors:  Natasha Duborija-Kovacevic; Milica Martinovic
Journal:  Multidiscip Respir Med       Date:  2012-06-21

Review 5.  New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?

Authors:  Izabela Kuprys-Lipinska; Marta Kolacinska-Flont; Piotr Kuna
Journal:  Clin Transl Allergy       Date:  2020-06-03       Impact factor: 5.871

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.